One Way Liver

OWL Metabolomics (One Way Liver, S.L.) is a Spanish biotechnology company specializing in the development of non-invasive diagnostic tests for liver diseases. The company utilizes a proprietary metabolomics and lipidomics platform to identify biomarkers in blood samples, offering an alternative to invasive liver biopsies. Its lead products, OWLiver and OWLiver Care, are designed for the diagnosis and management of Non-Alcoholic Steatohepatitis (NASH/MASH) and Non-Alcoholic Fatty Liver Disease (NAFLD/MASLD). Beyond diagnostics, OWL provides R&D services to pharmaceutical companies to support drug discovery and clinical trial stratification in the hepatology space. The company's technology is based on high-throughput mass spectrometry and advanced data science for metabolic profiling. In 2023, OWL Metabolomics was acquired by Laboratorios Rubió, integrating its diagnostic capabilities into a broader pharmaceutical and healthcare portfolio.